HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Wednesday, 21 December 2011

New NICE topic for HEDS

ScHARR-TAG have had a new NICE STA topic confirmed.  It is rivaroxaban (Xarelto, Bayer) for the treatment of acute coronary syndrome.

The draft scope is available (here).  It highlights two patient groups with different comparators.  For people who are to be managed with PCI; bivalirudin in combination with aspirin and clopidogrel, prasugrel in combination with aspirin, and ticagrelor in combination with aspirin (subject to ongoing NICE technology appraisal).  For people who are not to be managed with PCI; clopidogrel in combination with aspirin, and ticagrelor in combination with aspirin (subject to ongoing NICE technology appraisal).